Press Releases

Sydney, May 6, 2008 (ABN Newswire) - Ventracor Limited (ASX:VCR)(US:VTCRY) today announced that there have now been more than 250 patient implants of the VentrAssist(R) Left Ventricular Assist Device (LVAD).

There are now 36 centres in ten countries worldwide that have implanted the VentrAssist LVAD.

In the United States, clinical trials continue to gain momentum, with 59 patients enrolled in the Bridge to Transplant (BTT) Clinical Trial and 26 patients enrolled in the Destination Therapy (DT) clinical trial, in addition to the 28 patients implanted in the US Feasibility Trial which is now complete. There are now 19 centres in the US that have performed at least one implant of the VentrAssist LVAD, with 22 centres trained and ready to go.

Commenting on the achievement, Ventracor Chief Executive Officer Mr. Peter Crosby said: "Ventracor is pleased with the growing clinical confidence in the VentrAssist LVAD that comes with increasing data from many patients with good outcomes. The clinical results from the US feasibility trial that were presented at the International Society of Heart and Lung Transplantation in April compare favorably with all new generation LVADs."

Mr. Crosby further added: "We also applaud the US Food and Drug Administration (FDA) pre-market approval (PMA) of the first of the new generation rotary blood pumps, and anticipate that this will help validate the enormous potential of the worldwide LVAD market."

Ventracor's VentrAssist LVAD is a third generation centrifugal flow LVAD that is market released in Europe and Australia. It is one of only two devices in the US which has been implanted in both a BTT and DT clinical trial. There is more clinical experience with the VentrAssist LVAD than all other third generation centrifugal LVADs combined.

Contact

Graeme Fallet Chief Financial Officer Angela Edwards Investor Relations Tel: +61(2)9406 3100 www.ventracor.com